178 related articles for article (PubMed ID: 19755862)
1. Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells.
Wang J; Zhou JY; Zhang L; Wu GS
Cell Cycle; 2009 Oct; 8(19):3191-8. PubMed ID: 19755862
[TBL] [Abstract][Full Text] [Related]
2. Bim protein degradation contributes to cisplatin resistance.
Wang J; Zhou JY; Wu GS
J Biol Chem; 2011 Jun; 286(25):22384-92. PubMed ID: 21561860
[TBL] [Abstract][Full Text] [Related]
3. ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells.
Wang J; Zhou JY; Wu GS
Cancer Res; 2007 Dec; 67(24):11933-41. PubMed ID: 18089824
[TBL] [Abstract][Full Text] [Related]
4. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.
Dai Y; Jin S; Li X; Wang D
Oncotarget; 2017 Jan; 8(1):1354-1368. PubMed ID: 27935869
[TBL] [Abstract][Full Text] [Related]
5. High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma.
Wang Z; Zhou JY; Kanakapalli D; Buck S; Wu GS; Ravindranath Y
Pediatr Blood Cancer; 2008 Dec; 51(6):754-9. PubMed ID: 18726921
[TBL] [Abstract][Full Text] [Related]
6. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
7. ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells.
Xie Q; Su J; Jiao B; Shen L; Ma L; Qu X; Yu C; Jiang X; Xu Y; Sun L
Int J Oncol; 2016 Dec; 49(6):2507-2519. PubMed ID: 27748803
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance.
Wang Z; Xu J; Zhou JY; Liu Y; Wu GS
Cancer Res; 2006 Sep; 66(17):8870-7. PubMed ID: 16951204
[TBL] [Abstract][Full Text] [Related]
9. Difference in expression of Bcl-2 and Bcl-xl genes in cisplatin-sensitive and cisplatin-resistant human in ovarian cancer cell lines.
Yu L; Wang Z
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(2):151-3. PubMed ID: 15315167
[TBL] [Abstract][Full Text] [Related]
10. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
[TBL] [Abstract][Full Text] [Related]
11. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
12. Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.
Matsumura S; Ohta T; Yamanouchi K; Liu Z; Sudo T; Kojimahara T; Seino M; Narumi M; Tsutsumi S; Takahashi T; Takahashi K; Kurachi H; Nagase S
Cancer Biol Ther; 2017 Sep; 18(9):730-739. PubMed ID: 27689466
[TBL] [Abstract][Full Text] [Related]
13. Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis.
Brotin E; Meryet-Figuière M; Simonin K; Duval RE; Villedieu M; Leroy-Dudal J; Saison-Behmoaras E; Gauduchon P; Denoyelle C; Poulain L
Int J Cancer; 2010 Feb; 126(4):885-95. PubMed ID: 19634140
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
15. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.
Simonin K; Brotin E; Dufort S; Dutoit S; Goux D; N'diaye M; Denoyelle C; Gauduchon P; Poulain L
Mol Cancer Ther; 2009 Nov; 8(11):3162-70. PubMed ID: 19887550
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
18. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
[TBL] [Abstract][Full Text] [Related]
19. PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment.
Zhu X; Ji M; Han Y; Guo Y; Zhu W; Gao F; Yang X; Zhang C
Int J Oncol; 2017 Mar; 50(3):835-846. PubMed ID: 28197632
[TBL] [Abstract][Full Text] [Related]
20. MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.
Wang J; Kho DH; Zhou JY; Davis RJ; Wu GS
Oncogene; 2017 Oct; 36(43):5939-5947. PubMed ID: 28650468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
